Long-term results from two major clinical trials support transcatheter aortic valve replacement (TAVR) as an alternative to surgery, even in patients at low risk for surgical complications.
Edwards Lifesciences’ Sapien line of balloon-expandable TAVR and Medtronic’s CoreValve line of self-expanding TAVR systems are already approved by the US Food and Drug Administration for high-risk, intermediate-risk,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?